Biography
Dr. Petak is a biomedical scientist with 25+ years of experience in precision oncology. He is an adjunct professor of molecular pharmacology at the University of Illinois at Chicago (UIC), author of over 150 scientific publications focusing on precision medicine, and founder of the medical technology companies Oncompass Medicine and Genomate Health. He pioneered molecular pharmacology of programmed cell death in 1998, predictive molecular diagnostics of lung cancer in 2003 and next generation sequencing in molecular profiling of solid tumors in 2008. He led the development of a novel computational method that successfully implemented cognitive computing in precision oncology in 2021.

Talk
Computational Method to Improve Treatment Decisions in Precision Oncology
Genomate's computational reasoning AI model automatically matches treatment options to the combinations of the co-occurring, on average, 4-5 genetic driver alterations and biomarkers present in each tumor instead of linking therapies to individual biomarkers one by one.

AI and Data Sciences Showcase:
Genomate Health
Genomate Health Inc. is a digital health company (based in Cambridge, MA) that develops AI-powered computational tools for personalized medicine. Its main focus is assisting physicians in making optimal personalized treatment decisions for each patient based on the complex molecular characteristics of human diseases.

Biography
Dr. Grammer is an internationally recognized scientist and successful entrepreneur, having founded and managed AMPEL successfully for over 5 years. Dr. Grammer was elected to the class of 2021 for SIBF (Society of International Business Fellows), an organization of 1,400 individuals in 45 countries worldwide. She was also awarded a Virginia SBIG grant for AMPEL's first investment round. She is a second term board member of Virginia Bio. Before cofounding AMPEL in 2013, Dr. Grammer spent over 20+ years in genomics and managed more than 15 National Institute of Health (NIH) scientific teams and a highly productive NIH laboratory. Dr. Grammer received multiple awards for her team's work comparing genes expressed in patients compared with healthy individuals, including the prestigious NIH Director's Award as well as mentoring awards from the American Association of Immunologists. She has published over 75 articles on her scientific research.

Talk
RNA & Predictive AI Platform for Pharma Drug Development

AI and Data Sciences Showcase:
AMPEL BioSolutions
AMPEL is a precision medicine company with a development pipeline of CLIA-certified gene expression tests for blood or tissue samples that determine disease status, identify molecular pathway and predict best drugs. Genomic platform, bioinformatics, RNA analytics and ML/AI algorithms covered by patents & are disease agnostic.

Biography
Ben builds computational tools that make life science research faster, more productive, more social and more fun. As a leader of artificial intelligence research and development at Rosalind, Inc., he is currently laying the foundation for trustworthy and accountable generative A.I. services meant to assist scientists at every phase of the research cycle. Prior to joining Rosalind, Ben spent much of his career advancing systems that facilitate the collaborative creation of collective intelligence in biology including: the Gene Wiki, Wikidata, CIViC, and the Gene Ontology Initiative. He has published more than 80 scientific articles in domains ranging from machine learning to games with a scientific purpose.

Talk
Empowering Every Scientist with Collective Intelligence
At Rosalind, we believe the path to precision medicine will be found through a collective human intelligence now accelerated by generative AI. Using a BioIntelligence platform, collaborating researchers can harness the network of knowledge to refine their future research while gaining deeper understanding of fundamental biology.

AI and Data Sciences Showcase:
Rosalind
ROSALIND is the leading collaborative research platform for knowledge management and multi-omic data analysis. As a secure unified data hub for sequencing and multiplex technologies, ROSALIND combines deep interpretation and interactive visualization for spatial, single-cell, RNA, NanoString, and clinical data.

Biography
Dr. Feng spent over 20 years in precision medicine. Dr. Feng came from NovartisOncology Business Unit where she established international partnerships fortheir targeted cancer therapeutics programs. She joined Novartis through itsacquisition of Genoptix. Dr. Feng built the BioPharma division at Genoptix,where she grew the business from zero to $45M in five years by forging allianceswith pharmaceutical companies and providing companion diagnosticsdevelopment for targeted cancer therapies. The division was instrumental inGenoptix acquisition by Novartis for $500M.

AI and Data Sciences Showcase:
Huma.AI
Huma.AI is a pioneer in generative AI, providing its own “ChatGPT” for Life Sciences through direct collaboration with OpenAI. Huma.AI allows Life Science teams to comprehend the competitive landscape from multiple perspectives quickly.

Biography
Marco is a serial entrepreneur with a long history of leadership positions in companies that deliver cutting-edge innovations in healthcare and life sciences. Accelerating and amplifying the clinical impact of innovations is what drives him. Since 2012 he has been building data-related products and businesses. Gesund.ai is pioneering the validation of medical AI models prior to - or for - FDA-approval with its proprietary technology platform, annotators network, and partnerships. Gesund's platform dramatically improves collaboration between the data science team and other internal stakeholders. Gesund.ai's customers are pharmaceutical companies and medical device companies. Gesund.ai partners with healthcare providers in the US and abroad.

Talk
AI Factory: Scaling Multimodal AI to Accelerate Clinical Trials
We have to graduate from "one-off" data science projects that are good for publishing papers but not putting compliant AIML into production at scale. In this talk, we discuss how the Gesund nocode AI factory accelerates AIML RD cycles bringing multimodal data, models and board-certified experts together, to unlock scientific breakthroughs and supercharge clinical trials.

AI and Data Sciences Showcase:
Gesund.ai
Gesund.ai is a compliant MLOps platform solving the medical AI validation problem by bringing case-specific data, models and board-certified physician annotators together in a no-code environment. We create regulatory-grade evidence in a reproducible, auditable and scalable manner compliant with best practices posed by medical stakeholders.

Biography
A 25 year veteran of healthcare innovation, Carla Balch founded the Spesana Healthcare Platform for all therapeutic areas to increase precision medicine and break barriers to MDx test ordering. Carla grew up in the halls of medicine (oncology), research clinical trials, and patient reported outcomes. She served as CEO of Altos Solutions OncoEMR, the first oncology EMR and Clinical Decision Support (acquired by GVFlatiron then Roche). She holds patents in: 1) in multidomain decision support, and 2) machine vision for molecular diagnostics results and matching mutations to treatment or trials. Carla is a serial CEO with successful exists in health tech innovation, holds a Master's Degree is Clinical Psychology and was selected as Entrepreneur of the Year 2021 in Memphis, TN.

Talk
Overcoming Precision Medicine Gaps via Healthtech & AI

AI and Data Sciences Showcase:
Spesana
Spesana Healthcare Platform enables healthcare across states, specialties, and technology silos. HIPAA compliant Cloud-based Platform provides aggregated patient records, instant referrals, virtual collaboration boards, MDx ordering/results, precision medicine education, clinical trial tech, and full prior authorization.

Biography
Dr. Martin Stumpe serves as the Chief of AI at Tempus, where he leads the development of AI algorithms from NGS and digital pathology to improve clinical context and decision making for better patient care. Prior to Tempus, Dr. Stumpe founded and led the Cancer Pathology project at Google, which uses artificial intelligence to increase the accuracy in image based cancer detection and grading. Earlier in his career, Dr. Stumpe was part of the Kepler team at NASA Ames Research Center; and before that, he was a postdoctoral researcher at Stanford University focusing on molecular dynamics simulations to study chaperone induced protein folding. Dr. Stumpe holds a PhD in Computational and Theoretical Physics from the Max Planck Institute for Biophysical Chemistry in Goettingen, Germany.

AI and Data Sciences Showcase:
Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, Tempus enables physicians to deliver personalized patient care and accelerates the development of optimal therapeutics.

Biography
Elliott is the Cofounder and CEO of Dandelion. He was a founding member of Oscar Health, where he expanded Oscar's insurance business in response to the newly passed Affordable Care Act. He then coordinated Oscar's expansion into 10 additional states, ultimately conceiving, contracting, and operationalizing the OscarCleveland Clinic JV in Ohio and Oscar's partnership with Humana as they rolled out a small group plan in Nashville. After Oscar, Elliott joined TrialSpark as the Head of Commercial Strategy and Partnerships. There he focused on provider partnerships and company strategy as TrialSpark looked to create a new patient experience. These efforts resulted in TrialSpark achieving acclaim as an industry disrupter on its way to a valuation of more than $1B. Elliott then joined Clarify Health as SVP and GM to drive improvements in the patient journey through data.

Talk
Building a High Fidelity Real World Data Platform

AI and Data Sciences Showcase:
Dandelion Health
Dandelion is a product and data infrastructure platform catalysing the development of healthcare AI.

Biography
A seasoned leader with over 24 years experience in leading Digital Transformation, Healthcare Strategy, and Clinical Data Operations. With a strong risk and quality mindset, I collaborate to deliver solutions that have the best value outcomes.

Talk
Loneliness Kills: Nextgen Humanoid Support for Clinicians in Healthcare

AI and Data Sciences Showcase:
Machani Group
Machani Robotics is part of a self-funded, AI Venture Studio that has launched multiple startups, each dedicated to solving real-world social issues.RIA, is an AI-enabled Companion Humanoid, designed to alleviate loneliness among senior adults, support mental health and assist clinicians in their daily operations

Biography
Leads scientific research and various high impact partnerships for nference. An alumni and Postdoctoral Fellow of Stanford University with a Ph.D. in Computational Biology from the university of Cambridge. Worked as an investigator for Novartis Institutes for BioMedical Research (NIBR) prior to joining nference.

Talk
Reimagining Biomedicine in the Age of AI
Deep learning tools can analyze medical images with greater accuracy than the human eye. This is particularly relevant in fields such as radiology pathology, where AI can help identify anomalies in PET scans, and MRIs and biopsy slides, contributing significantly to the early detection of diseases or treatment pathways.

AI and Data Sciences Showcase:
nference
nference partners with health systems to transform decades of rich and predominantly unstructured data captured in EMR into powerful software solutions that enable scientists to discover and develop personalized dx and treatments for patients worldwide.

Biography
Dr. Adhami is a clinical medical oncologist hematologist who works with the TriHealth Cancer Institute in Cincinnati and is an integral part of a strong Informatics program. He trained at University of Cincinnati where he completed his combined MDPhD program and Internal Medicine residency, then trained in HematologyOncology at UT Southwestern. As the Physician Informaticist for TCI, he is a leading innovator both in Informatics and in Precision Medicine.

AI and Data Sciences Showcase:
TriHealth Cancer Ins
TriHealth Cancer & Blood Institute provides multidisciplinary care, with specialty physicians focused on each form of cancer. Providing care for the whole person with centers located throughout the region making it easier for our patients to access care.

Biography
Arnout Van Hyfte’s journey with BioStrand, now a subsidiary of IPA (ImmunoPrecise Antibodies), began in 2019 as a key member of the founding team. He has played a pivotal role in shaping the company's commercial strategies, setting the stage for its remarkable growth, and building a robust infrastructure that forms the very foundation of BioStrand's operations. Arnout oversees the development team, ensuring their seamless coordination and fostering a culture of innovation. His leadership extends to crafting effective sales and marketing strategies, as well as engaging with the market to cultivate meaningful relationships.

Talk
Integration of Wet Lab and In Silico
IPA integrates the antibody discovery and characterization process with a pioneering neurosymbolic approach to identify optimal candidates. Through harmonizing knowledge layers with unstructured data our method relies on transparency and enhances precision. The goal is to provide program managers and scientists with a combination of desired functionality and provide patient population specific insights.

AI and Data Sciences Showcase:
ImmunoPrecise (IPA)
ImmunoPrecise is a biotherapeutic research hub leveraging systems biology, multiomics modeling and complex artificial intelligence systems to support its proprietary antibody discovery technologies. Combining an AI driven approach with best-in-class laboratory capabilities creates a powerful synergy that is revolutionizing antibody discovery.

Biography
Rami is the global head of software and Informatics development at Illumina. He joined Illumina in 2018 as part of the Edico Genome acquisition and has continuously expanded his leadership, which now includes overseeing all of instrument software, cloud platforms, bioinformatics and clinical software across Illumina's entire portfolio. Over the past few years, Ramis organization has helped establish Illumina as a leading provider in informatics, delivering innovative, reliable software products developed in deep collaborations with KOLs.

Talk
AI and ML Advances in Genomic Sequencing and Multiomics
Artificial intelligence and machine learning in multiomic applications are accelerating the pace of discoveries in healthcare. With these, Illumina is improving variant calling accuracy with DRAGEN, variant prioritization with Emedgene's Explainable AI, and impact prediction with PrimateAI3D. Learn how novel approaches are increasing the speed and accuracy of health insights.

AI and Data Sciences Showcase:
Illumina
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

Biography
Michael Boice has over 20 years of experience in translational oncology drug development, from bench science to business development. As Senior Director, Scientific Engagement and Key Accounts at Certis Oncology Solutions, Michael works directly with biopharmaceutical clients to enhance their preclinical programs through a collaborative approach to scientific problem-solving and optimized study designs. Michael's areas of expertise include the development of novel oncology therapeutics, functional genomics, and rare cancers. He holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences, Department of Pharmacology Memorial Sloan Kettering Cancer Center, Cancer Biology and Genetics.

Talk
Certisai Predictive Oncology Intelligence in Precision Oncology
AI is reshaping the drug discovery landscape and bringing new insights to cancer research. Explore how in silico efficacy predictions, when validated in advanced models, can bring greater certainty to early decisionmaking, and improve clinical translation. Learn how AI can bring precision to biomarker discovery, model selection and patient stratification.

AI and Data Sciences Showcase:
Certis Oncology
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence™ — highly predictive therapeutic response data derived from AI-enabled insights and validated in advanced biological models of cancer.

Biography
Craig Knox draws on his more than 15 years of experience in computing science, genetics, and metabolomics and bioinformatics research to guide DrugBanks rapid growth. For a decade, Craig served as a bioinformatician and team lead at the University of Albertas Genome Canada Helpdesk. He then went on to work as a software engineer in Santa Monica before co-founding a global bioinformatics consulting company. Today, as co-founder and CTO of DrugBank, Craig leads an impressive team of software developers and curators, focusing on technology strategy and alignment, AI applications, and data integration and quality.

Talk
Data Centric AI, Why it Matters
A brief introduction to data-centric AI - an exciting shift that is taking place in how researchers, data scientists, and organizations are approaching AI, and in particular how these changes might impact the healthcare spectrum.

AI and Data Sciences Showcase:
DrugBank
DrugBank is the world's first intelligent and comprehensive drug knowledge platform. With the help of artificial intelligence, our expert team authors, verifies, and structures all of the latest biomedical information so that it can be used to its fullest potential.

Biography
Joe is a leader in KPMGs Precision Medicine practice. He has 14 years of experience in the Life Sciences industry across both strategy consulting and directly scaling pharma-enabling technology organizations. Joe’s consulting experience ranges across deal evaluation and diligence, product and pipeline prioritization, and launch strategy for biopharma, life sciences tools and software, CROsCDMOs, and private investors. Within industry, Joe has held Commercial leadership roles at TrialSpark and Tempus, where he developed and expanded strategic partnerships with pharma and biotech organizations across RD, Commercial, and Med Affairs organizations. Joe has worked across multiple therapeutic areas, including oncology (drugs, diagnostics, services), neuroscience (psychiatry, neurocognition, neuroinflammation, imaging), immunology, ophthalmology, cardiovascular metabolic, as well as rare diseases.

Talk
Precision Medicine: AI's Transformative Impact
Join us as we explore AI's transformative influence on Precision Medicine. From patient risk assessments to tailored treatments, we'll highlight generative AI's role and address emerging challenges like data privacy and ethics. Concluding, we'll guide through potential solutions, emphasizing the pivotal role of federated learning and other innovative processes.

AI and Data Sciences Showcase:
KPMG US
KPMG’s Precision Medicine practice is part of KPMG Healthcare and Life Sciences, supporting the development and execution of strategies across the HCLS continuum. Our practice is a leader across therapeutic areas and global markets, fueled by experience across the value chain.

Biography
Harry Nunns leads the MultiOmyx analytics team and oversees the development of NeoGenomics AIbased image analysis pipeline. His focus is on applying deep learning tools to extract accurate spatially resolved data from multiplex immunofluorescence images.

Talk
Digital Image Analysis of the Tumor Microenvironment
The role of AI and digital image analysis in generating insights from HE, IHC multiplex IF datasets.

AI and Data Sciences Showcase:
NeoGenomics
NeoGenomics is a leading oncology testing company.

Biography
For the past five years, Ted has leveraged AI techniques to advance the field of precision medicine diagnostics. During his time at Scipher Medicine, he made significant contributions to the creation and successful launch of PrismRA, a groundbreaking molecular signature response classifier that utilizes patient gene expression signatures to accurately predict response to TNFinhibitor therapy. Notably, this pioneering test has garnered Medicare approval for coverage, marking a significant milestone in the field of personalized medicine in immunology. Before joining Scipher, Ted received his PhD in Engineering from Dartmouth College. His research primarily centered around diagnostic development, employing machine learning methodologies and extensive omics datasets to drive innovation in healthcare diagnostics.

Talk
Large Genomic Models Using Largest Clinico-Genomic Registry in Immunology
Discover novel molecular markers through the utilization of extensive genomic data. This presentation explores the potential for enhancing predictive models with generative AI using the largest clinicogenomic registry in immunology

AI and Data Sciences Showcase:
Scipher Medicine
Scipher Medicine® is a precision immunology company on a mission to match each patient with their most effective therapy to improve health outcomes.

Biography
Maddison is a strong believer in the power of engineering to advance the world of life sciences and to accelerate biological discovery. She invented Deepcells AI-based single-cell analysis and sorting technology with her postdoctoral advisor Euan Ashley and Mahyar Salek, and spun the company out of Stanford University in 2017. Originally from Tehran, Iran, she has a multidisciplinary background with experience in electrical engineering, computer science, and bioengineering. Maddison holds a bachelors degree in electrical engineering from Sharif University of Technology, as well as a masters degree in computer science and a PhD in bioengineering from the University of California, Los Angeles. She has published several papers in top-tier journals and has co-invented multiple patented technologies.

AI and Data Sciences Showcase:
Deepcell
Deepcell is blending AI powered technology, microfluidics and high resolution optics across biological domains. Fostering pioneering insights through multiple perspectives. Fueling perpetual discoveries and changing how our community approaches cell science as a whole.

Biography
Rosh Singh has over a decade of experience in driving innovations in biomedical engineering and healthcare, navigating complex operational and data challenges to implement solutions at scale. He is particularly recognized for streamlining areas such as value based care, risk adjustment, and population health through Cozeva, the flagship product of Applied Research Works, where he serves as the CTO. This product caters to over 18 million patients and collaborates with an expansive network of primary care providers, health plans, and provider organizations. Singh's innovative approach to seamlessly integrating data driven solutions into care delivery has been pivotal in transforming healthcare outcomes and reducing burdens on care teams.

Talk
Elevating Care Quality Beyond Reductionist Measures
Current care quality measures often simplify complex care scenarios for easier tracking. With AI advancements, a balanced approach now facilitates nuanced pointofcare assessments, promoting alignment with broader reporting mandates. This direction not only enhances precision but fosters a more accurate reflection of care quality.

AI and Data Sciences Showcase:
Cozeva - ARW
Cozeva, a payer and EHR agnostic cloud SaaS pop health and analytics platform utilizing FHIR, aggregates clinical data in 20 states for 50+ provider organizations and 10 health plans. It offers real-time point-of-care insights, enhancing care quality and risk management, benefiting 18 million members nationwide.

Biography
Xin Xie has been practicing law with an emphasis on patent law since 2012. He has worked with artificial intelligence (AI) and medical related technologies, among many other technical fields. Previously, Xin was an Examiner at the US Patent Office. Xin was also a Medical Device Fellow at the Food and Drug Administration, where he assessed the safety and efficacy of medical devices to evaluate their compliance with medical device laws. In addition to his legal experience, Xin also has engineering experience at St. Jude Medical and at startups.

Talk
AI in Regenerative Medicine: Patent Law Updates and Regulatory Implications
With the meteoric growth of AI, specifically in regenerative medicine, regulations are constantly updating. For example, in the patent law space, new guidelines have been promulgated and new case law has been enacted regarding patent eligibility of AI and medicine. We will cover these new developments to navigate the new regulatory and patent landscape.

AI and Data Sciences Showcase:
Attorney
Xin Xie has been practicing law with an emphasis on patent law since 2012. He has worked with artificial intelligence (AI) and medical related technologies, among many other technical fields.

Biography
Václav is a Founder and Board Director of Optellum (Oxford, UK), a lung health startup providing a AI-powered decision support platform that assists physicians in early diagnosis and optimal treatment of lung cancer, the first such software to secure FDA and CEMDR clearance, and CMS Medicare reimbursement under New Technology APC. Prior to founding Optellum he launched novel medical robotics devices as Global Product Manager at Hocoma, the global market leader in neurorehabilitation exoskeletons. Václav holds Oxford University Doctorate (D.Phil) in Machine Learning in collaboration with Siemens Healthineers and Mirada Medical, and Cambridge University M.Phil in Computational Biology. With his PhD supervisors (and later Optellum cofounders) Prof. Sir Mike Brady FRS and Dr. Timor Kadir they pioneered the application of computer vision to lung cancer therapy planning. He has worked and studied in eleven countries and speaks seven languages.

Talk
Enabling Early Diagnosis and Precision nmNSCLC Treatment with AI "Radiomics"
Lung cancer shows no symptoms until advanced stage. Automated analysis of 90M CT scans US patients receive p.a., such as emergency and cardiac studies, enables an "early identification system" to radically reshape outcomes. Leveraging powers of NLP and "Radiomics" to drive tiniest tumours into followup intervention, and deliver precision nmNSCLC treatment with targeted and immunotherapies.

AI and Data Sciences Showcase:
Optellum Ltd.
Optellum a lung health startup providing a AI-powered decision support platform that assists physicians in early diagnosis and optimal treatment of lung cancer, the first such software to secure FDA and CE-MDR clearance, and CMS Medicare reimbursement under New Technology APC.

Biography
Co-founder of Gero, a data-driven longevity biotech company that develops new drugs against aging and other complex diseases using AI-platform. An author of 75+ published papers in multiple domain areas, including publications in Science and Nature Communications. Ph.D. from the University of Amsterdam.

AI & Data Science Showcase:
Gero.AI
Gero is an AI-driven drug discovery company focused on therapies targeting aging and age-related diseases.

GERO AI: Drug Discovery Against Complex Diseases
Gero has developed a platform for targets and biomarkers of aging identification. Recently Gero demonstrated outstanding results rejuvenating mice and extending their maximum lifespan in the lab of one of the top researchers in the field - Brian Kennedy.

Biography
Michael Boice, PhD, has over 20 years of experience in translational oncology drug development, from bench science to business development. He works directly with biopharmaceutical clients to enhance their preclinical programs through a collaborative approach to scientific problemsolving and optimized study designs. Michaels areas of scientific expertise include the development of novel oncology therapeutics, functional genomics, and rare cancers.

Talk
CertisAI Predictive Oncology Intelligence In Precision Medicine
AI is reshaping the drug discovery landscape and bringing new insights to cancer research. Explore how in silico efficacy predictions, when validated in advanced models, can bring greater certainty to early decisionmaking, and improve clinical translation. Learn how AI can bring precision to biomarker discovery, model selection and patient stratification.

AI and Data Sciences Showcase:
Certis Oncology
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Certis Oncology Intelligence - highly predictive therapeutic response data derived from AI-enabled insights and validated in advanced biological models of cancer.

Biography
Dr. Costes, boasts a rich background in research leadership, spanning renowned institutions like the National Cancer Institute and the Lawrence Berkeley National Lab. He's also the cofounder and former CEO of Exogen Biotechnology Inc. Currently, Dr. Costes serves as the Chief for the Space Biosciences Research Branch and leads the Ames radiation biophysics laboratory at NASA Ames Research Center. Moreover, he manages all Open Science databases within the NASA Biological and Physical Science Division, overseeing initiatives in systems biology research, AIML modeling, and software development for the Open Science Data Repositories, including GeneLab and ALSDA. These repositories grant crucial access to spaceflight related data and samples. Beyond NASA, Dr. Costes is as a member of the White House's Cancer Cabinet, where he spearheads projects like Image Processing and Data Storage Frameworks under the Data Innovation Task Force, making significant strides in data-driven healthcare solutions and scientific advancements.

Talk
NASA Open Science Data Repositories (OSDR) for Space Biology
Addressing deep space mission challenges, NASA's Open Science Data Repositories (OSDR) facilitate open access to space biology data spanning microbes to humans, including all omics, physiological and phenomics data. OSDR ensures data discoverability and reproducibility, supporting experiments on genetic resilience to the space environment and advancing AI in space biology research.

AI and Data Sciences Showcase:
NASA
NASA Ames' Space Biosciences Division confronts the formidable challenges of spaceflight, where lower gravity, limited resources, and higher radiation levels pose significant risks to all forms of life. Addressing these issues is crucial for successful exploration of the moon, Mars, and beyond.

Biography
I am Professor at The Jackson Laboratory for Genomic Medicine, leading a lab that studies problems at the intersections of computational biology, cancer, and spatial data science, especially: development of interpretable methods for deep learning-based tissue image analysis; mechanistic and evolutionary analysis of multiplex image data including spatial transcriptomics and spatial proteomics; and the application of such methods to clinical and patient-derived cancer model tissues to develop new clinical trials. My current projects include leadership of the Data Commons and Coordination Center of the National Cancer Institute (NCI) Patient-Derived Xenograft Network Consortium; major roles in the NCI PIVOT Pediatric Cancer Testing Consortium and the NIH Senescence Network Consortium; and diverse studies to quantify intratumoral heterogeneity and improve outcomes for patients with cancer types including breast cancer, colorectal cancer, and melanoma. I am also Deputy Director of The Jackson Laboratory Cancer Center and leader of the JAX Cancer Advanced Technology program.

Talk
AI Approaches for Interpreting Cancer Topography
Recent multiplex imaging technologies have dramatically improved our ability to quantify the spatial topography of biological tissues, including both the cells and their surrounding environments. I will discuss how new spatial data science approaches combining deep neural networks and mechanistically interpretable methods can improve cancer prediction and treatment.

AI and Data Sciences Showcase:
Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research institution with a mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information visit www.jax.org.

Biography
Kenneth is CEO and co-founder of ViewsML. He previously co-founded Wax-it Histology Services, a contract research organization focused in histopathology for drug research. Kenneth has over 20 years of experience in management, product management, marketing and medical affairs. He has held various leadership roles in start-up, mid-size, and multinational life science and pharmaceutical companies. Most recently, Kenneth led global strategy, capabilities development, and Key Opinion Leader management at Eli Lilly.

Talk
Next Generation Immunohistochemistry: Multiplexing AI Virtual Biomarkers
Immunohistochemistry (IHC) and multiplexing are key for elucidating biomarker spatial expression in precision medicine. This talk will describe a novel AI-driven approach to bypass these wet lab processes to produce instant predicted virtual results. Use cases for this technology encompass translational research through to patient enrichment and stratification in clinical trials.

AI and Data Sciences Showcase:
ViewsML
ViewsML is transforming spatial biology for translational research and precision medicine using AI deep learning. By virtualizing immunohistochemistry (IHC) and biomarkers, we give researchers back 100% of their IHC time, 50% of their budget and richer data sets - representing a 15X ROI.

Biography
Backed by his expertise in molecular diagnostics, molecularly targeted drug discovery and development, biochemistry and regulatory compliance, Rob Fraser drives the innovation behind Molecular Yous multi-omic AI-powered analytics platform. Under his direction, Molecular You has established an affordable, comprehensive method of measuring hundreds of biomarkers from a single blood sample, and a LLM and ML model to incorporate the worlds leading scientific literature and collected data to accurately predict individual and population health risks.Previously, as the Chief Operating Officer of the Personalized Medicine Initiative, Rob supported the establishment of six new companies including Molecular You. Rob has also been involved in leading drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD.

Talk
AI-Powered Multi-Omic Health Analytics
Precision medicine is achieved through the absolute quantification and AI-powered analysis of multiple omics, particularly metabolites, proteins, and environmental exposures to provide a holistic view of a patient's health and risks.We will explore and demonstrate the advantages of an AI-powered, multi-omic approach in understanding and predicting health outcomes to better optimize care and costs.

AI and Data Sciences Showcase:
Molecular You
Molecular You is the first and only multi-biomarker analytics platform, providing decision support to clinicians and ACOs based on highly accurate predictive risk profiles in 26+ health areas.

Biography
Mr. Marcin Burda, Biomedical Scientist at Pangaea Data, is a passionate scientist and entrepreneur. With a background in academia, Marcin has specialized in cancer research and, prior to Pangaea, he worked in biotech on a team developing a groundbreaking immunotherapy. As the leader of Pangaea's biomedical team, Marcin works closely with Pangaea's customers and partners which has enabled him to successfully secure and deliver on several deals with global pharmaceutical companies looking to increase their revenues and improve patient outcomes through the application of Pangaea's product. Marcin takes an active role on the front-lines of Pangaea's USA and EU-UK business, currently managing projects worth $10 million, while helping identify new clinical pain points with prospective customers, converting these into further opportunities for Pangaea's product to benefit clinicians and patients a-like.

Talk
Crafting Personalized Care with AI and Data
Learn how NHS clinicians applied Pangaea to find and connect to 6x more undiagnosed and miscoded cachectic cancer patients compared to generic natural language processing (NLP) and ICD approaches. This led to a 50% reduction in treatment costs resulting in annual savings of 1B for the NHS coupled with improved resource allocation and patient outcomes.

AI and Data Sciences Showcase:
Pangaea Data
Pangaea’s product platform combines clinical guidelines and AI to find and connect to more undiagnosed patients for 7,000 hard-to-diagnose conditions across 140,000 healthcare providers globally. This is improving patient outcomes, halving treatment costs and enabling privacy-preserving and scalable collaboration between pharmaceutical and healthcare providers.

Biography
Dr. David oversees the deployment of QUREs proprietary provider engagement platform, which measures clinical care decisions made by providers nationwide, by presenting them with de novo virtual patients. Medical decision science is integral to evaluating the design, translation, market access, and adoption of novel diagnostics and therapeutics. Through his work at QURE, Dr. David has contributed to the accelerated integration of precision health technologies into practice, as well as the advancement of evidence-based care. Dr. David regularly collaborates with leaders in precision health and large health systems. Over the course of his career, Dr. David has held various board positions, adviserships, and appointments in industry, government, and academia.

Talk
Informing Translational Science with Medical Decision-Making Data
Two of the greatest challenges in precision health are translational science and technology integration into healthcare delivery. By engaging providers with customized virtual patients and carefully collecting resultant decision-making data, one can accurately assess their knowledge of precision tools, as well as diagnostic and therapeutic pathways in line with personalized and value-based care.

AI and Data Sciences Showcase:
QURE Healthcare
QURE Healthcare presents nationwide samples of healthcare providers with de novo virtual patients on a digital platform, to capture the clinical decisions being made with precision diagnostics and therapeutics. Results inform payer coverage and reimbursement (clinical utility), health system adoption, and market access strategy.

Biography
Dr. Mark Kiel completed his M.D., Ph.D., and Molecular Genetic Pathology Fellowship at the University of Michigan, where his research focused on stem cell biology, genomic profiling of hematopoietic malignancies, and clinical bioinformatics. He is the founder and chief scientific officer at Genomenon, where he oversees the company's scientific direction and product development. A genomic intelligence company, Genomenon was founded by Mark in 2014 to address the challenge of connecting pharma researchers with evidence in the genomic literature to help diagnose and treat patients with genetic diseases and cancer.

Talk
Understanding Gene-Disease Relationships: A Novel and Actionable Approach
The increasing use of large gene panels for genetic diseases has created a strain on labs to interpret this data. There is a need to appreciate a wider array of gene-disease relationships to accommodate a more diverse set of diseases. We'll discuss this growing need, describe the challenges, and how to solve them at scale.

AI and Data Sciences Showcase:
Genomenon
Genomenon is a genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for diagnosis and precision medicine.

Biography
She is a co-founder of enGenome and holds a Master's Degree in Biomedical Engineering, as well as a Ph.D. in Bioengineering and Bioinformatics. She is an expert in genomic data analysis and the development of bioinformatics tools. Currently, she serves as the Chief Science Officer at enGenome SRL, utilizing her extensive academic expertise to spearhead innovative projects and propel scientific progress within the organization. Her current focus is on harnessing generative AI technologies to enhance genomic data analysis.

Talk
Generative AI to Interpret Human Genomic Variations
In the fast-paced field of genomics, professionals struggle to keep up with vast, growing data. This challenge is critical in interpreting genomic variants, where timely, relevant literature is key. To aid this, VarChat (varchat.engenome.com) uses AI to condense scientific findings on genetic variants into clinically relevant summaries, linking to original sources for further research.

AI & Data Science Showcase:
EnGenome SRL
enGenome SRL is a cutting-edge bioinformatic company with the mission of enhancing healthcare with advanced genomics and AI. EnGenome has developed the eVai platform, to enable precise and early diagnosis of Rare Disease ensuring unprecedented accuracy in interpreting genomic variants.

Biography
Dr. Bruna Gomes is a cardiologist trained at the Heidelberg University Hospital in Germany. She obtained her medical degree at the Faculty of Medicine of the University of Coimbra, Portugal. As a cardiologist resident, she obtained considerable experience in distinct clinical settings varying from diverse cardiology wards to echocardiography, interventional cardiology, and cardiac MRI. During this period, she expanded her quantitative skill set to include biostatistics and bioinformatics (with special focus in deep learning and computer vision) to address open issues in diagnosing and treating structural heart disease. Since July 2021 she is a postdoctoral researcher at Stanford University, currently refining her bioinformatics research skills at Prof. Ashleys lab.

AI and Data Sciences Showcase:
Stanford
Stanford University, situated in Silicon Valley, is a prestigious institution known for its groundbreaking research and innovation. Its campus serves as a catalyst for creativity and has had a significant impact on the tech industry's development.

Biography
Karen Malone is dedicated closing the gap in drug development strategies for innovative, personalized therapies, by mapping the unmet need for inherited rare, ultra-rare, and orphan diseases. She founded GeneScape® to help inform drug development planning, with the goal of accelerating advanced therapeutics to these patients. GeneScape® leverages the latest in large-scale human genetic diversity data and machine learning tools to provide actionable data and reliable patient models to address some of the most challenging rare diseases. Dr. Malone is a molecular biologist and geneticist with a track-record of over 15 years of drug development experience, including prior scientific roles at Janssen Pharmaceuticals. Her work has covered the entire development path from discovery to pivotal trials, and new product planning. She has supported the development of a range of therapeutic modalities including genetic therapies for numerous indications and published more than 11 scientifically peer-reviewed papers.

Talk
GeneScape: Mapping Inherited Rare Disease Patient Populations
Dr. Malone will present GeneScape’s platform and recent examples of how their research has informed various programs by 1) quantifying the scale of unmet need, 2) estimating specific patient subsets, 3) identifying highest probability regions for finding patients, and 5) understanding the importance of patient genetic diversity within specific indications.

AI and Data Sciences Showcase:
GeneScape
GeneScape® is specialized in epidemiology for inherited rare, ultra-rare and orphan diseases. We leverage the latest in large-scale genetic diversity data to deliver actionable insights to streamline drug development. GeneScape® is a compass to navigate and transform your programs for rare, ultra-rare and orphan diseases.